Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025

Reuters11-24

<a href="https://laohu8.com/S/ADPT">Adaptive Biotechnologies</a> Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025

Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology $(ASH)$, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2585820464?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-24 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2585820464","market":"us","top_or_hot":-1,"title":"Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a>, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-24 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a>, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7k0hg2:1","article_id":"2585820464","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2585820464","pubTimestamp":1763987415,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ test for measurable residual disease  assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology , scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","ADPT":"Adaptive Biotechnologies Corp","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4121":"生命科学工具和服务","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4588":"碎股"},"translate_title":"Adaptive Biotechnologies在ASH 2025上以89份摘要展示clonoSEQ MRD测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"ADPT":0.9},"content_text":"Adaptive Biotechnologies Showcases clonoSEQ MRD Testing in 89 Abstracts at ASH 2025\n    \n\n        Adaptive Biotechnologies Corporation announced that its next-generation sequencing-based clonoSEQ® test for measurable residual disease (MRD) assessment will be featured in 89 abstracts, including 36 oral presentations, at the 67th Annual Meeting of the American Society of Hematology $(ASH)$, scheduled for December 6-9, 2025, in Orlando. The abstracts will highlight the use of clonoSEQ MRD testing across a range of blood cancers, including multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma. The presentations will include data on clonoSEQ's role in informing patient treatment decisions in real-world clinical practice and its use in clinical trials for assessing responses to novel therapies. The results will be presented at the upcoming ASH conference.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adaptive Biotechnologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9591019-en) on November 24, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585820464","isCrawlerRequest":true}